BioSyent

BioSyent OCF/Debt

The Operating Cash Flow to Debt Ratio of BioSyent (RX.V) as of Oct 9, 2026 is 834.87 %. In the previous year, Operating Cash Flow to Debt Ratio was 477.12 % — a change of 74.98% (higher).

OCF/Debt

834.87 %

YoY

74.98%

Last updated:

Operating Cash Flow to Debt Ratio of BioSyent is 2024 834.87 % . Operating Cash Flow to Debt Ratio of BioSyent was 2023 477.12 % . It decreases by 74.98% higher compared to the previous year.

The BioSyent OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
257.46 CAD
Jan 1, 2020
403.44 CAD
Jan 1, 2021
300.27 CAD
Jan 1, 2022
354.72 CAD
Jan 1, 2023
477.12 CAD
Jan 1, 2024
834.87 CAD
The BioSyent OCF/Debt history
YEAROCF/DebtYoY
834.87 %+74.98%
477.12 %+34.51%
354.72 %+18.14%
300.27 %-25.57%
403.44 %+56.70%
257.46 %—
Access this data via the Eulerpool API

BioSyent Stock analysis

What does BioSyent do? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioSyent stock

Operating Cash Flow to Debt Ratio of BioSyent is 834.87 % in 2024.

Operating Cash Flow to Debt Ratio of BioSyent changed from 477.12 % to 834.87 %, representing a 74.98% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio BioSyent since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's BioSyent with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — BioSyent

All Key Metrics — BioSyent